1. Home
  2. LLY vs NVO Comparison

LLY vs NVO Comparison

Compare LLY & NVO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Eli Lilly and Company

LLY

Eli Lilly and Company

HOLD

Current Price

$1,191.86

Market Cap

979.6B

Sector

Health Care

ML Signal

HOLD

Logo Novo Nordisk A/S

NVO

Novo Nordisk A/S

HOLD

Current Price

$45.83

Market Cap

208.2B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
LLY
NVO
Founded
1876
1923
Country
United States
Denmark
Employees
N/A
69500
Industry
Biotechnology: Pharmaceutical Preparations
Biotechnology: Biological Products (No Diagnostic Substances)
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
979.6B
208.2B
IPO Year
2007
N/A

Fundamental Metrics

Financial Performance
Metric
LLY
NVO
Price
$1,191.86
$45.83
Analyst Decision
Strong Buy
Hold
Analyst Count
19
11
Target Price
$1,218.84
$51.00
AVG Volume (30 Days)
2.0M
10.5M
Earning Date
04-30-2026
05-06-2026
Dividend Yield
0.81%
3.19%
EPS Growth
95.99
N/A
EPS
16.19
N/A
Revenue
$65,179,000,000.00
N/A
Revenue This Year
$27.15
N/A
Revenue Next Year
$16.04
$3.70
P/E Ratio
$141.50
$13.60
Revenue Growth
44.70
N/A
52 Week Low
$623.78
$35.12
52 Week High
$1,249.45
$64.16

Technical Indicators

Market Signals
Indicator
LLY
NVO
Relative Strength Index (RSI) 57.00 40.53
Support Level $1,032.70 $42.72
Resistance Level $1,240.73 $46.92
Average True Range (ATR) 34.58 1.34
MACD -3.78 -0.75
Stochastic Oscillator 78.01 21.22

Price Performance

Historical Comparison
LLY
NVO

About LLY Eli Lilly and Company

Eli Lilly is a drug firm with a focus on neuroscience, cardiometabolic, cancer, and immunology. Lilly's key products include Verzenio and Jaypirca for cancer; Mounjaro, Zepbound, Foundayo, Jardiance, Trulicity, Humalog, and Humulin for cardiometabolic; and Taltz and Olumiant for immunology.

About NVO Novo Nordisk A/S

With roughly one-third of the global branded diabetes treatment market, Novo Nordisk is the leading provider of diabetes care products in the world. Based in Denmark, the company manufactures and markets a variety of human and modern insulins, injectable diabetes treatments such as GLP-1 therapy, oral antidiabetic agents, and obesity treatments. Novo also has a biopharmaceutical segment (contributing less than 10% of revenue) that specializes in protein therapies for hemophilia and other disorders.

Share on Social Networks: